B7-1 and B7-2 selectively recruit CTLA-4 and CD28 to the immunological synapse.

[1]  G. Freeman,et al.  An autoimmune disease-associated CTLA-4 splice variant lacking the B7 binding domain signals negatively in T cells. , 2004, Immunity.

[2]  D. Sansom,et al.  CD86 and CD80 Differentially Modulate the Suppressive Function of Human Regulatory T Cells1 , 2004, The Journal of Immunology.

[3]  Oreste Acuto,et al.  CD28-mediated co-stimulation: a quantitative support for TCR signalling , 2003, Nature Reviews Immunology.

[4]  P. Loke,et al.  B7x: A widely expressed B7 family member that inhibits T cell activation , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[5]  D. Sansom,et al.  What's the difference between CD80 and CD86? , 2003, Trends in immunology.

[6]  Luc J. Smink,et al.  Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease , 2003, Nature.

[7]  S. Almo,et al.  Crystal structure of the receptor-binding domain of human B7-2: Insights into organization and signaling , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[8]  Andrea Iaboni,et al.  The interaction properties of costimulatory molecules revisited. , 2002, Immunity.

[9]  Michael S. Kuhns,et al.  CTLA-4: new insights into its biological function and use in tumor immunotherapy , 2002, Nature Immunology.

[10]  V. Kuchroo,et al.  Inhibition of CTLA-4 Function by the Regulatory Subunit of Serine/Threonine Phosphatase 2A1 , 2002, The Journal of Immunology.

[11]  D. Litchfield,et al.  A novel costimulatory signaling in human T lymphocytes by a splice variant of CD28. , 2002, Blood.

[12]  Andrea Iaboni,et al.  The immunological synapse and CD28-CD80 interactions , 2001, Nature Immunology.

[13]  Yan Zhang,et al.  Crystal structure of the B7-1/CTLA-4 complex that inhibits human immune responses , 2001, Nature.

[14]  A. Fedorov,et al.  Structural basis for co-stimulation by the human CTLA-4/B7-2 complex , 2001, Nature.

[15]  J. Allison,et al.  Cytotoxic T lymphocyte antigen-4 (CTLA-4) regulates the size, reactivity, and function of a primed pool of CD4+ T cells. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[16]  K. Hathcock,et al.  Blockade of Costimulation Through B7/CD28 Inhibits Experimental Autoimmune Uveoretinitis, But Does Not Induce Long-Term Tolerance , 2000, The Journal of Immunology.

[17]  S. Almo,et al.  Structure of murine CTLA-4 and its role in modulating T cell responsiveness. , 2000, Science.

[18]  P. Tipping,et al.  B7.1 and B7.2 co‐stimulatory molecules regulate crescentic glomerulonephritis , 2000, European journal of immunology.

[19]  Saito,et al.  Treatment with anti‐CD86 costimulatory molecule prevents the autoimmune lesions in murine Sjögren's syndrome (SS) through up‐regulated Th2 response , 2000, Clinical and experimental immunology.

[20]  J. Bluestone,et al.  A Critical Role for B7/CD28 Costimulation in Experimental Autoimmune Encephalomyelitis: A Comparative Study Using Costimulatory Molecule-Deficient Mice and Monoclonal Antibody Blockade1 , 2000, The Journal of Immunology.

[21]  A. Sharpe,et al.  B7 costimulation in the development of lupus: autoimmunity arises either in the absence of B7.1/B7.2 or in the presence of anti-b7.1/B7.2 blocking antibodies. , 1999, Journal of immunology.

[22]  A. Sharpe,et al.  The role of CD80, CD86, and CTLA4 in alloimmune responses and the induction of long-term allograft survival. , 1999, Journal of immunology.

[23]  G. Sharp,et al.  B7.2 has opposing roles during the activation versus effector stages of experimental autoimmune thyroiditis. , 1999, Journal of immunology.

[24]  Colin R. F. Monks,et al.  Three-dimensional segregation of supramolecular activation clusters in T cells , 1998, Nature.

[25]  W. Heath,et al.  Defective TCR expression in transgenic mice constructed using cDNA‐based α‐ and β‐chain genes under the control of heterologous regulatory elements , 1998, Immunology and cell biology.

[26]  E. Simpson,et al.  B7-1 and B7-2 have overlapping, critical roles in immunoglobulin class switching and germinal center formation. , 1997, Immunity.

[27]  G. Nolan,et al.  Episomal vectors rapidly and stably produce high-titer recombinant retrovirus. , 1996, Human gene therapy.

[28]  I. Kariv,et al.  Analysis of the site of interaction of CD28 with its counter-receptors CD80 and CD86 and correlation with function. , 1996, Journal of immunology.

[29]  R. Karr,et al.  Differential effects of CTLA-4 substitutions on the binding of human CD80 (B7-1) and CD86 (B7-2). , 1996, Journal of immunology.

[30]  J. Bluestone,et al.  Blockade of CD28/B7-1 interaction prevents epitope spreading and clinical relapses of murine EAE. , 1995, Immunity.

[31]  M. Azuma,et al.  Preferential dependence of autoantibody production in murine lupus on CD86 costimulatory molecule , 1995, European journal of immunology.

[32]  R. Karr,et al.  Antigen-dependent clonal expansion of a trace population of antigen-specific CD4+ T cells in vivo is dependent on CD28 costimulation and inhibited by CTLA-4. , 1995, Journal of immunology.

[33]  Laurie H Glimcher,et al.  B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: Application to autoimmune disease therapy , 1995, Cell.

[34]  J. Bluestone,et al.  Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse , 1995, The Journal of experimental medicine.

[35]  P. Linsley,et al.  Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors. , 1994, Immunity.

[36]  P. Linsley,et al.  Complementarity determining region 1 (CDR1)- and CDR3-analogous regions in CTLA-4 and CD28 determine the binding to B7-1 , 1994, The Journal of experimental medicine.

[37]  P. Linsley,et al.  Comparative analysis of B7-1 and B7-2 costimulatory ligands: expression and function , 1994, The Journal of experimental medicine.

[38]  T. Hawley,et al.  Versatile retroviral vectors for potential use in gene therapy. , 1994, Gene therapy.

[39]  J. Bluestone,et al.  Expression and functional significance of an additional ligand for CTLA-4. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[40]  G. Freeman,et al.  Uncovering of functional alternative CTLA-4 counter-receptor in B7-deficient mice. , 1993, Science.

[41]  P. Linsley,et al.  Coexpression and functional cooperation of CTLA-4 and CD28 on activated T lymphocytes , 1992, The Journal of experimental medicine.

[42]  Arthur Weiss,et al.  Genetic evidence for the involvement of the lck tyrosine kinase in signal transduction through the T cell antigen receptor , 1992, Cell.

[43]  R. Schwartz,et al.  A cell culture model for T lymphocyte clonal anergy. , 1990, Science.

[44]  F. Denizot,et al.  A new member of the immunoglobulin superfamily—CTLA-4 , 1987, Nature.

[45]  L. Arnold,et al.  Antigen-induced lymphomagenesis: identification of a murine B cell lymphoma with known antigen specificity. , 1983, Journal of immunology.

[46]  J. Egen,et al.  Cytotoxic T lymphocyte antigen-4 accumulation in the immunological synapse is regulated by TCR signal strength. , 2002, Immunity.

[47]  J. Bluestone,et al.  Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. , 2001, Annual review of immunology.